Leadman's first-half loss widens to 7.11 million yuan

Earnings
โดย 财中社·CN·Read original
Summary · why it matters

Leadman published its 2026 interim report. First-half operating revenue was 152 million yuan, down 5.3 percent year on year, while net profit attributable to the parent swung from a loss of 4.25 million yuan a year earlier to a loss of 7.11 million yuan. Second-quarter operating revenue was 81.5 million yuan, down 0.1 percent year on year, and the net loss attributable to the parent was 3.14 million yuan, wider than the 2.99 million yuan loss in the same period last year. As of the end of the second quarter, total assets were 1.756 billion yuan, down 1.1 percent from the end of the previous year, and net assets attributable to the parent were 1.632 billion yuan, down 0.4 percent. In vitro diagnostic reagents remained the main revenue source, generating 111 million yuan, up 1.69 percent year on year and accounting for 72.85 percent of operating revenue. Diagnostic instruments brought in 17.23 million yuan, down 24.23 percent, representing 11.34 percent of revenue. Biochemical raw materials contributed 6.81 million yuan, down 11.32 percent, or 4.48 percent of revenue. Other businesses generated 17.22 million yuan, down 18.75 percent, or 11.33 percent of revenue. The company's operating model is mainly distribution-based, with distribution revenue of 123 million yuan accounting for 90.98 percent of main business revenue, while direct sales revenue was 12.16 million yuan, or 9.02 percent. The company flagged risks including changes in industry policy and intensifying market competition, and said it has taken measures to address them.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews